Tags

Type your tag names separated by a space and hit enter

[Developments in the medical treatment of overactive bladder].
Semergen. 2016 Nov - Dec; 42(8):557-565.S

Abstract

Overactive Bladder (OAB) is a common problem among men and women. Antimuscarinic drugs are a reference treatment for OAB and act by blocking the muscarinic receptors (M2 and M3 subtypes) in the bladder. Adherence to antimuscarinic treatment is usually low, due to the perceived lack of efficacy and adverse effects. Therefore, new treatments with different mechanisms of action and a more acceptable tolerability profile are needed, and that improve the symptoms of OAB. Mirabegron is a new treatment option for all patients with OAB and could solve an unmet need in patients still not satisfied, or where the antimuscarinic therapy is not indicated, is an alternative option for patients with OAB.

Authors+Show Affiliations

Centro de Salud José María Álvarez , Don Benito, Badajoz, España; Miembro del Grupo de Trabajo de Nefrourología de SEMERGEN. Electronic address: a.alcantara.montero@hotmail.com.

Pub Type(s)

Journal Article
Review

Language

spa

PubMed ID

26671329

Citation

Alcántara Montero, A. "[Developments in the Medical Treatment of Overactive Bladder]." Semergen, vol. 42, no. 8, 2016, pp. 557-565.
Alcántara Montero A. [Developments in the medical treatment of overactive bladder]. Semergen. 2016;42(8):557-565.
Alcántara Montero, A. (2016). [Developments in the medical treatment of overactive bladder]. Semergen, 42(8), 557-565. https://doi.org/10.1016/j.semerg.2015.10.006
Alcántara Montero A. [Developments in the Medical Treatment of Overactive Bladder]. Semergen. 2016 Nov - Dec;42(8):557-565. PubMed PMID: 26671329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Developments in the medical treatment of overactive bladder]. A1 - Alcántara Montero,A, Y1 - 2015/12/04/ PY - 2015/09/01/received PY - 2015/10/05/revised PY - 2015/10/11/accepted PY - 2015/12/17/pubmed PY - 2017/5/26/medline PY - 2015/12/17/entrez KW - Agonistas beta-3 adrenérgicos KW - Beta 3 adreno-receptor agonists KW - Mirabegron KW - Mirabegrón KW - Overactive bladder KW - Vejiga hiperactiva SP - 557 EP - 565 JF - Semergen JO - Semergen VL - 42 IS - 8 N2 - Overactive Bladder (OAB) is a common problem among men and women. Antimuscarinic drugs are a reference treatment for OAB and act by blocking the muscarinic receptors (M2 and M3 subtypes) in the bladder. Adherence to antimuscarinic treatment is usually low, due to the perceived lack of efficacy and adverse effects. Therefore, new treatments with different mechanisms of action and a more acceptable tolerability profile are needed, and that improve the symptoms of OAB. Mirabegron is a new treatment option for all patients with OAB and could solve an unmet need in patients still not satisfied, or where the antimuscarinic therapy is not indicated, is an alternative option for patients with OAB. SN - 1578-8865 UR - https://www.unboundmedicine.com/medline/citation/26671329/[Developments_in_the_medical_treatment_of_overactive_bladder]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1138-3593(15)00342-1 DB - PRIME DP - Unbound Medicine ER -